Bone Biologics shares surge 20.32% premarket as rhNELL-1 shelf life extended to 24 months, boosting manufacturing efficiency and commercialization readiness.

Bone Biologics surged 20.32% in premarket trading following the confirmation that its rhNELL-1 product shelf life has been extended to 24 months. The milestone, validated by stability data, marks a progression from prior 12- and 18-month validations and is expected to enhance manufacturing efficiency, supply-chain flexibility, and commercial readiness. The CEO emphasized the achievement as a critical step toward commercialization, aligning with the company’s long-term strategy to advance rhNELL-1 as a differentiated bone growth factor for spinal fusion procedures. The announcement reinforces confidence in operational execution and shareholder value creation, directly correlating with the stock’s sharp premarket rally.